BSH 2022 - 62nd British Society for Haematology Annual Scientific Meeting
Apr 03 - Apr 05, 2022 | ManchesterUK
LARVOL is not affiliated with 62nd British Society for Haematology Annual Scientific Meeting and all trademarks, logos, and brand names are property of their respective owners
Showing 46 abstracts linked to Trials
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia: Final 5-year Results From the BFORE Trial
Sudden or Cardiac Deaths on Ibrutinib-Based Therapy were associated with a prior History of Hypertension or Cardiac Disease and the use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide + Rituximab (R2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Efficacy of Mogamulizumab in Mycosis Fungoides by Patient Blood Involvement and Time to Response Analysis in Mycosis Fungoides and Sézary Syndrome: A post hoc analysis of the MAVORIC Study
Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial
Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results
Efficacy and safety of avapritinib as first-line treatment of patients with advanced systemic mastocytosis: Results of EXPLORER and PATHFINDER clinical study
Long-term Survival Benefit of Eculizumab Treatment in Patients With Paroxysmal Nocturnal Haemoglobinuria: Data From the International PNH Registry
Analysis Of Anaemia Persistence And Related Adverse Events In Patients With Paroxysmal Nocturnal Haemoglobinuria Treated With Pegcetacoplan
Etavopivat, an investigational, once-daily, selective pyruvate kinase-R activator, improves sickle red blood cell health and survival in patients with sickle cell disease: an analysis of exploratory studies in a phase 1 trial
Pharmacokinetic/Pharmacodynamic Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia
Does Early Intervention in Myelofibrosis Impact Outcomes? A Pooled Analysis of the COMFORT I and II Studies
Pegcetacoplan Treatment In Patients With Paroxysmal Nocturnal Haemoglobinuria And Baseline Haemoglobin Levels At Or Above 10 g/dl
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomised, open-label study of eculizumab and ravulizumab in complement inhibitor-naïve patients with paroxysmal nocturnal haemoglobinuria (PNH)
Pegcetacoplan Patient Compliance Rates In PEGASUS And PRINCE Phase 3 Trials Compared To Published Oral Medication Compliance Rates In Literature